Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.62 |
| ▸ | RAB9A | P51151 | 2/20 | 0.62 |
| ▸ | HDAC3 | O15379 | 4/20 | 0.56 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.54 |
| ▸ | MAOB | P27338 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | BLM | P54132 | 1/20 | 0.53 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 2/20 | 0.52 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.52 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.52 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.52 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.52 |
| ▸ | NAMPT | P43490 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27996132 | 0.93 | HDAC1 (0.60) | NPC1RAB9AHDAC3HDAC1HDAC6 | |
| SCHEMBL28362105 | 0.93 | HDAC1 (0.60) | NPC1RAB9AHDAC3HDAC1HDAC6 | |
| SCHEMBL14159023 | 0.91 | CYP1A2 (0.63) | NPC1RAB9ACYP1A2TSHRNFKB1 | |
| SCHEMBL3505666 | 0.89 | CYP1A2 (0.68) | NPC1RAB9AHDAC3HDAC1CYP1A2 | |
| Hydrochloric Acid SCHEMBL3945078 | 0.87 | KMT2A (0.69) | NPC1RAB9AHDAC3HDAC1CYP1A2 | |
| SCHEMBL3523157 | 0.85 | MAPK1 (0.61) | NPC1RAB9AHDAC3HDAC1CYP1A2 | |
| SCHEMBL455890 | 0.84 | HDAC3 (0.58) | NPC1RAB9AHDAC3HDAC1CYP1A2 | |
| SCHEMBL2302774 | 0.84 | NPC1 (0.64) | NPC1RAB9AKMT2AMEN1POLB | |
| SCHEMBL17623623 | 0.84 | HDAC3 (0.59) | NPC1RAB9AHDAC3HDAC1CYP1A2 | |
| SCHEMBL12960847 | 0.83 | MAPK1 (0.65) | NPC1RAB9AHDAC3HDAC1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3196194-B1 | PYRIMIDINE DERIVATIVES USEFUL AS SELECTIVE JAK3 AND/OR JAK1 INHIBITORS | SHENZHEN CHIPSCREEN BIOSCIENCES LTD (CN) | 2019-08-07 | — | — | EP | disclosed |
| EP-3196194-B1 | PYRIMIDINE DERIVATIVES USEFUL AS SELECTIVE JAK3 AND/OR JAK1 INHIBITORS | SHENZHEN CHIPSCREEN BIOSCIENCES LTD (CN) | 2019-08-07 | — | — | EP | disclosed |
| US-10011571-B2 | Preparation method for aromatic heterocyclic compound used as selective JAK3 and/or JAK1 kinase inhibitor and application of aromatic heterocyclic compound | SHENZHEN CHIPSCREEN BIOSCIENCES, LTD. (CN) | 2018-07-03 | — | — | US | disclosed |
| US-10011571-B2 | Preparation method for aromatic heterocyclic compound used as selective JAK3 and/or JAK1 kinase inhibitor and application of aromatic heterocyclic compound | SHENZHEN CHIPSCREEN BIOSCIENCES, LTD. (CN) | 2018-07-03 | — | — | US | disclosed |
| US-10011571-B2 | Preparation method for aromatic heterocyclic compound used as selective JAK3 and/or JAK1 kinase inhibitor and application of aromatic heterocyclic compound | SHENZHEN CHIPSCREEN BIOSCIENCES, LTD. (CN) | 2018-07-03 | — | — | US | disclosed |
| CN-105399685-B | The alternatively preparation method and applications of the heteroaromatic compounds of property JAK3 and/or JAK1 kinase inhibitors | 深圳微芯生物科技有限责任公司 | 2018-05-22 | — | — | CN | disclosed |
| US-20170253566-A1 | PREPARATION METHOD FOR AROMATIC HETEROCYCLIC COMPOUND USED AS SELECTIVE JAK3 AND/OR JAK1 KINASE INHIBITOR AND APPLICATION OF AROMATIC HETEROCYCLIC COMPOUND | SHENZHEN CHIPSCREEN BIOSCIENCES, LTD. (CN) | 2017-09-07 | — | — | US | disclosed |
| US-20170253566-A1 | PREPARATION METHOD FOR AROMATIC HETEROCYCLIC COMPOUND USED AS SELECTIVE JAK3 AND/OR JAK1 KINASE INHIBITOR AND APPLICATION OF AROMATIC HETEROCYCLIC COMPOUND | SHENZHEN CHIPSCREEN BIOSCIENCES, LTD. (CN) | 2017-09-07 | — | — | US | disclosed |
| US-20170253566-A1 | PREPARATION METHOD FOR AROMATIC HETEROCYCLIC COMPOUND USED AS SELECTIVE JAK3 AND/OR JAK1 KINASE INHIBITOR AND APPLICATION OF AROMATIC HETEROCYCLIC COMPOUND | SHENZHEN CHIPSCREEN BIOSCIENCES, LTD. (CN) | 2017-09-07 | — | — | US | disclosed |
| EP-3196194-A1 | PREPARATION METHOD FOR AROMATIC HETEROCYCLIC COMPOUND USED AS SELECTIVE JAK3 AND/OR JAK1 KINASE INHIBITOR AND APPLICATION OF AROMATIC HETEROCYCLIC COMPOUND | Shenzhen Chipscreen Biosciences, Ltd. (CN) | 2017-07-26 | — | — | EP | disclosed |
| EP-3196194-A1 | PREPARATION METHOD FOR AROMATIC HETEROCYCLIC COMPOUND USED AS SELECTIVE JAK3 AND/OR JAK1 KINASE INHIBITOR AND APPLICATION OF AROMATIC HETEROCYCLIC COMPOUND | Shenzhen Chipscreen Biosciences, Ltd. (CN) | 2017-07-26 | — | — | EP | disclosed |
| WO-2016041472-A1 | PREPARATION METHOD FOR AROMATIC HETEROCYCLIC COMPOUND USED AS SELECTIVE JAK3 AND/OR JAK1 KINASE INHIBITOR AND APPLICATION OF AROMATIC HETEROCYCLIC COMPOUND | 深圳微芯生物科技有限责任公司 | 2016-03-24 | — | — | WO | disclosed |
| CN-105399685-A | Preparation method and applications of aromatic heterocyclic compound adopted as selective JAK3 and/or JAK1 kinase inhibitor | SHENZHEN CHIPSCREEN BIOSCIENCES LTD | 2016-03-16 | — | — | CN | disclosed |
| EP-1012147-B1 | O-SUBSTITUTED HYDROXYCUMARANONE DERIVATIVES AS ANTITUMOR AND ANTIMETASTATIC AGENTS | HOFFMANN LA ROCHE (CH) | 2005-11-02 | — | — | EP | disclosed |
| CN-1129591-C | Ortho-substituted hydroxybenzofuran-3-one derivatives as antitumor and antimetastatic agents | HOFMANN LA ROCHE AG F (CH) | 2003-12-03 | — | — | CN | disclosed |
| US-6200989-B1 | ADMINISTERING AS UROKINASE PLASMINOGEN ACTIVATOR ANTAGONISTS, ANTITUMOR AND ANTIMETASTASIS AGENTS | HOFFMANN-LA ROCHE INC. | 2001-03-13 | — | — | US | disclosed |
| CN-1265656-A | O-substituted hydroxycumaranone derivatives as anttumor and antimetastatic agents | HOFFMANN LA ROCHE (CH) | 2000-09-06 | — | — | CN | disclosed |
| EP-1012147-A2 | O-SUBSTITUTED HYDROXYCUMARANONE DERIVATIVES AS ANTITUMOR AND ANTIMETASTATIC AGENTS | F. HOFFMANN-LA ROCHE AG (CH) | 2000-06-28 | — | — | EP | disclosed |
| WO-1999006387-A2 | O-SUBSTITUTED HYDROXYCUMARANONE DERIVATIVES AS ANTITUMOR AND ANTIMETASTATIC AGENTS | F. HOFFMANN-LA ROCHE AG (CH) | 1999-02-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10011571-B2 | Preparation method for aromatic heterocyclic compound used as selective JAK3 and/or JAK1 kinase inhibitor and application of aromatic heterocyclic compound | JAK3, JAK1, JAK2 | NPC1 3598/4885RAB9A 1878/4885HDAC3 749/4885 |
| US-20170253566-A1 | PREPARATION METHOD FOR AROMATIC HETEROCYCLIC COMPOUND USED AS SELECTIVE JAK3 AND/OR JAK1 KINASE INHIBITOR AND APPLICATION OF AROMATIC HETEROCYCLIC COMPOUND | JAK3, JAK1, JAK2 | NPC1 3598/4885RAB9A 1878/4885HDAC3 749/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.